The issued patent covers the Dosage Manager device platform developed by OnDosis for dosing of oral solid medicines in the form of pellets.
The issued patent is the first relating to OnDosis device and its core design and functionality, and the company expects further patents to follow in due course from the company’s extensive patent portfolio, it states.
“We are very pleased with this first issued patent for our invention, the Dosage Manager, which is now at final stage of development and expected to undergo a regulatory approval process in the US during 2024 as a part of a drug/device combination aimed to improve treatment of patients with ADHD,” says Martin Olovsson, CEO at OnDosis. “The US is the most important market for us at this stage since this is where we target our first launch, and due to its size and its openness to innovation. We are very excited by the fact that our first issued patent is in the US.”
OnDosis have several development projects ongoing in collaboration with Tiefenbacher Group (Hamburg, Germany) under the OYSTA brand, and with other undisclosed biopharmaceutical companies. The first project in collaboration with Tiefenbacher is expected to reach the US market in 2025, aiming to improve treatment for patients with ADHD.
Besides ADHD, other CNS related diseases as well as cardiovascular, oncology, orphan and pediatric indications are in focus for future developments.
Photo of Martin Olovsson: OnDosis/HR Foto